Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects

Drug Metabolism and Disposition

Volumn 40, Issue 8, 2012, Pages 1466-1472

  Nicolas, Jean Marie ^a   Chanteux, H ^a   Rosa, M ^a   Watanabe, S ^a   Stockis, A ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVARACETAM; BRIVARACETAM DERIVATIVE; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; DRUG METABOLITE; GEMFIBROZIL; GEMFIBROZIL 1 O BETA GLUCURONIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYDROXYLATION; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; URINARY EXCRETION;

ANTICONVULSANTS; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; GEMFIBROZIL; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MICROSOMES, LIVER; PYRROLIDINONES;

BREDA VIRUS;

EID: 84863886221     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.112.045328     Document Type: Article

References (44)

1. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691.
2. Deng LJ, Wang F, and Li HD (2005) Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur J Clin Pharmacol 61:831-836.
3. Farmer JA (2001) Learning from the cerivastatin experience. Lancet 358:1383-1385.
4. French JA, Costantini C, Brodsky A, von Rosenstiel P, and N01193 Study Group (2010) Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 75:519-525.
5. Gillard M, Fuks B, Leclercq K, and Matagne A (2011) Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol 664:36-44.
6. Hinton LK, Galetin A, and Houston JB (2008) Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharm Res 25:1063-1074.
7. Huang SM, Strong JM, Zhang L, Reynolds KS, Nallani S, Temple R, Abraham S, Habet SA, Baweja RK, Burckart GJ, et al. (2008) New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48:662-670.
8. Huang SM, Temple R, Throckmorton DC, and Lesko LJ (2007) Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 81:298-304.
9. Jenkins SM, Zvyaga T, Johnson SR, Hurley J, Wagner A, Burrell R, Turley W, Leet JE, Philip T, and Rodrigues AD (2011) Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil. Drug Metab Dispos 39:2421-2430.
10. Karonen T, Filppula A, Laitila J, Niemi M, Neuvonen PJ, and Backman JT (2010) Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin Pharmacol Ther 88:223-230.
11. Karonen T, Neuvonen PJ, and Backman JT (2011) The CYP2C8 inhibitor gemfibrozil does not affect the pharmacokinetics of zafirlukast. Eur J Clin Pharmacol 67:151-155.
12. Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW, and Zhou SF (2009) Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab 10:1009-1047.
13. Mano Y, Usui T, and Kamimura H (2007) The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos 35:2040-2044.
14. Naritomi Y, Terashita S, and Kagayama A (2004) Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 34:415-427.
15. Nebot N, Crettol S, d'Esposito F, Tattam B, Hibbs DE, and Murray M (2010) Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 161:1059-1069.
16. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, and Neuvonen PJ (2003) Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 46: 1319-1323.
17. Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, and Neuvonen PJ (2005) Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. Br J Clin Pharmacol 60:208-217.
18. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, and Kivistö KT (2002) Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 72:326-332.
19. Niemi M, Neuvonen PJ, and Kivistö KT (2001) Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride. Clin Pharmacol Ther 70:439-445.
20. Niemi M, Tornio A, Pasanen MK, Fredrikson H, Neuvonen PJ, and Backman JT (2006) Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. Eur J Clin Pharmacol 62:463-472.
21. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197.
22. Parkinson A, Kazmi F, Buckley DB, Yerino P, Ogilvie BW, and Paris BL (2010) System-dependent outcomes during the evaluation of drug candidates as inhibitors of cytochrome P450 (CYP) and uridine diphosphate glucuronosyltransferase (UGT) enzymes: human hepatocytes versus liver microsomes versus recombinant enzymes. Drug Metab Pharmacokinet 25:16-27.
23. Rolan P, Sargentini-Maier ML, Pigeolet E, and Stockis A (2008) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 66:71-75.
24. Rostami-Hodjegan A and Tucker GT (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
25. Sabordo L, Sallustio BC, Evans AM, and Nation RL (1999) Hepatic disposition of the acyl glucuronide 1-O-gemfibrozil-β-D-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation. J Pharmacol Exp Ther 288:414-420.
26. 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 36:36-45.
27. Sargentini-Maier ML, Rolan P, Connell J, Tytgat D, Jacobs T, Pigeolet E, Riethuisen JM, and Stockis A (2007) The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol 63:680-688.
28. Sargentini-Maier ML, Sokalski A, Boulanger P, Jacobs T and Stockis A (2012) Brivaracetam disposition in renal impairment. J Clin Pharmacol doi:10.1177/0091270011431457.
29. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, and Raza A (2004) The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455-463.
30. Shitara Y, Hirano M, Sato H, and Sugiyama Y (2004) Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
31. Shon JH, Yoon YR, Kim MJ, Kim KA, Lim YC, Liu KH, Shin DH, Lee CH, Cha IJ, and Shin JG (2005) Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. Br J Clin Pharmacol 59:552-563.
32. Stockis A, Watanabe S, Rouits E, Matsuguma K, and Irie S (2011) Double-blind, placebo-controlled single and multiple rising dose study of brivaracetam in healthy Japanese male subjects - influence of CYP2C19 genotype. Proceedings of the 65th Annual Meeting of the American Epilepsy Society; 2011 Dec 2-6; Baltimore, MD. American Epilepsy Society, West Hartford, CT.
33. Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, and Backman JT (2008) The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther 84:403-411.
34. van Giersbergen PL, Treiber A, Clozel M, Bodin F, and Dingemanse J (2002) In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 71:253-262.
35. van Paesschen W, Brodsky A, and von Rosenstiel P (2007) Efficacy and tolerability of 50 and 150 mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial onset epilepsy. Epilepsia 48 (Suppl 6):329.
36. Wen X, Wang JS, Backman JT, Kivistö KT, and Neuvonen PJ (2001) Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 29:1359-1361.
37. Werhahn KJ, Biton V, Johnson ME, Merschhemke M, and Lu S (2010) Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from two randomized, double-blind, placebo-controlled trials. Epilepsia 51 (Suppl 4):150.
38. Whitfield LR, Porcari AR, Alvey C, Abel R, Bullen W, and Hartman D (2011) Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin. J Clin Pharmacol 51:378-388.
39. Whomsley R, Brochot A, Dell'Aiera S, Delepine X, and Espie P (2007) Identification of the cytochrome P450 isoforms responsible for the hydroxylation of brivaracetam. AAPS J 9 (Suppl 2):T3408.
40. Yin OQ, Tomlinson B, and Chow MS (2005) CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther 78:370-377.
41. Zhang H, Davis CD, Sinz MW, and Rodrigues AD (2007) Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667-687.
42. Zhou L, Naraharisetti SB, Liu L, Wang H, Lin YS, Isoherranen N, Unadkat JD, Hebert MF, and Mao Q (2010) Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos 31:228-242.
43. + current in rat cortical neurons in culture. Epilepsy Res 88:46-54.
44. Zou L, Harkey MR, and Henderson GL (2002) Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 71:1579-1589.